

4th

SOHO MENA

PROGRAM

DATE
SEPTEMBER
25-26, 2026

VENUE
Radisson Blu Hotel
Verdun - Beirut

**9 CME
CREDITS**



Welcome Letter



Dear Colleagues and Friends,

It is with great pleasure that we welcome you to the **4th SOHO MENA Conference** that will be held in **September 25-26 at Radisson Hotel** . For the fourth consecutive year, we are proud to host this important scientific gathering, bringing together healthcare professionals, experts, researchers, and colleagues from across the region and beyond to exchange knowledge, share experiences, and explore the latest developments in hematologic malignancies.

This year, we are pleased to present a rich and comprehensive scientific program, covering key advances, emerging research, and current challenges in the field. The program will feature the participation of distinguished international guest speakers from the United States and Europe, in addition to renowned experts and leaders from across the MENA region and Lebanon ensuring a diverse and engaging exchange of knowledge and perspectives.

Over the past years, **the SOHO MENA** Conference has continued to grow into a valuable platform for scientific collaboration, education, and meaningful dialogue. This fourth edition reflects our continued commitment to providing a high-quality educational experience and fostering collaboration among the hematology community.

As Co-Chairs of the Conference, we are delighted to welcome you once again and look forward to your participation in what promises to be another enriching and inspiring edition.

Thank you for being part of the **4th SOHO MENA** Conference. We look forward to welcoming you and sharing this exciting scientific journey together.

Warm regards,

Ali Bazarbachi, MD
Co-Chair

Ahmad Ibrahim, MD
Co-Chair

Georges Chahine, MD
Co-Chair

Elias Jabbour, MD
Co-Chair

FACULTY MEMBERS

**Ahmad Ibrahim, MD**

Makassed Hospital, Beirut, Lebanon

**Ali Bazarbachi, MD**

American University of Beirut, Lebanon

**Amer Zeidan, MD**

Yale University, USA

**Anna Sureda, MD**

Institut Català d'Oncologia
Hospitalet, Barcelona, Spain

**Courtney DiNardo, MD**

University of Texas MD Anderson Cancer
Center, Houston, USA

**Elias Jabbour, MD**

University of Texas MD Anderson Cancer
Center, Houston, USA

**Farhad Ravandi, MD**

University of Texas MD Anderson Cancer
Center, Houston, USA

**Ghandi Damaj, MD**

Hematology Institute at the University
Hospital, Normandy University, Caen, France

**Gilles Salles, MD**

Memorial Sloan Kettering Cancer Center, USA

**Giuseppe Saglio, MD**

University of Turin, Turin, Italy

**Hagop Kantarjian, MD**

University of Texas MD Anderson Cancer
Center, Houston, USA

**Hanan Hamed, MD**

Ain Shams University

**Ibrahim Yakoub-Agha, MD**

Lille University, France

**Luis Fayad, MD**

M. D. Anderson Cancer Center, USA

**Mohamad Mohty, MD**

Saint-Antoine Hospital and Sorbonne
University, Paris, France

**Mohamed Kharfan-Dabaja, MD**

Mayo Clinic in Florida

**Naval Daver, MD**

University of Texas MD Anderson Cancer
Center, Houston, USA

**Nitin Jain, MD**

The University of Texas MD Anderson
Cancer Center, USA

**Olivier Hermine, MD**

Hôpital Necker-Enfants Malades,
Paris, France

**Paolo Strati, MD**

University of Texas MD Anderson Cancer
Center, Houston, TX, USA

**Rachid Baz, MD**

Moffitt Cancer Center

**Rami Komrokji, MD**

Moffitt Cancer Center, Tampa, Florida, USA

**Rami Mahfouz, MD**

American University of Beirut, Lebanon

**Robin Foà, MD**

Sapienza University of Rome, Italy

**Stephane de Botton, MD**

Institut Gustave Roussy, France

**Talha Munir, MD**

Leeds Teaching Hospitals NHS Trust, UK

**Tapan Kadia, MD**

University of Texas MD Anderson Cancer Center,
Houston, USA

**Thierry Facon, MD**

Lille University Hospital, Lille, France and French
National Academy of Medicine, Paris, France

Day 1: September 25, 2026



08:00 - 08:45 Registration

08:45 - 09:00 Welcome Address

SESSION 1: MYELOPROLIFERATIVE NEOPLASMS - CHRONIC MYELOID LEUKEMIA

Moderators: Issam Chehade, MD - Mohammad Haidar, MD - Clemence Matta, MD

09:00 - 09:15 Current Challenges in the Management of Primary Myelofibrosis **Ibrahim Yakoub-Agha, MD**

09:15 - 09:35 Modern Approaches in Essential Thrombocythemia and Polycythemia Vera **Hanan Hamed, MD**

09:35 - 09:50 Chronic Myeloid Leukemia: Choosing Wisely from Different Treatment Options **Hagop Kantarjian, MD**

09:50 - 10:05 Chronic Myeloid Leukemia: Immune Surveillance and Treatment-Free Remission **Giuseppe Saglio, MD**

10:05 - 10:15 **Q&A**

SESSION 2: CHRONIC LYMPHOCYTIC LEUKEMIA

Moderators: Ahmad Younes, MD - Oussama Safar, MD - Pamela Sfeir, MD

10:15 - 10:30 Current Treatment Strategy in Chronic Lymphocytic Leukemia **Nitin Jain, MD**

10:30 - 10:45 Double Refractory Patients with Chronic Lymphocytic Leukemia: What Can We Do? **Mohamed Kharfan-Dabaja, MD**

Day 1: September 25, 2026



10:45 - 11:05 Fixed-Duration MRD-Adapted Therapy vs Indefinite Therapy in First Line. Yes (10') / No (10')

Nitin Jain, MD
vs
Talha Munir, MD

11:05 - 11:15 Q&A

11:15 - 11:40  COFFEE BREAK

11:40 - 12:10 Changing The Narrative In Mds: From Underdiagnosis To Modern Management.

Symposium Sponsored
by Bristol Myers Squibb

Imane Abou Dalle, MD

SESSION 3: LYMPHOMA (I)

Moderators: Ali Youssef, MD - Joseph Makdessi, MD - Mirna Hajj, MD

12:10 - 12:30 New Agents in Mantle Cell Lymphoma

Olivier Hermine, MD

12:30 - 12:50 Update in the Management of T-cell Lymphoma

Ghandi Damaj, MD

12:50 - 13:10 Update in the First Line Treatment of Hodgkin Lymphoma

Anna Sureda, MD

13:10 - 13:30 Treatment Sequencing and Role of Transplant and Cellular Therapy in Hodgkin Lymphoma

Ali Bazarbachi, MD

13:30 - 13:40 Q&A

13:40 - 14:40  LUNCH BREAK

Day 1: September 25, 2026



14:40 - 15:10	Symposium : Darzalex, the foundational therapy for MM <i>Moderator: Dr Ahmad Ibrahim</i>	Symposium Sponsored by Johnson & Johnson	Nour Moukalled, MD
15:10 - 15:25	Q&A		
SESSION 4: MYELOYDYSPLASTIC SYNDROMES <i>Moderators: Abdel Fattah Kheir, MD - Bassam Mattar, MD</i>			
15:25 - 15:45	Optimizing Front-Line Therapy to Improve Outcome in Low-Risk Myelodysplastic Syndromes		Rami Komrokji, MD
15:45 - 16:05	Update in the Management of High-Risk Myelodysplastic Syndromes		Amer Zeidan, MD
16:05 - 16:15	Q&A		
16:15 - 16:30	 COFFEE BREAK		
16:30 - 17:15	Symposium: Optimizing Treatment Sequences in DLBCL: Therapeutic Management in the Post-R-CHOP Era	Symposium Sponsored by Roche	Andrew Davies, MD
SESSION 5: ACUTE MYELOID LEUKEMIA <i>Moderators: Iman Abou Dalle, MD - Ahmad Khalil, MD - Oussama Jradi, MD - Hampig Kourie, MD</i>			
17:15 - 17:30	Optimizing Frontline Therapies in Acute Myeloid Leukemia		Tapan Kadia, MD
17:30 - 17:45	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: ELN Minimal Residual Disease Recommendations		Rami Mahfouz, MD

Day 1: September 25, 2026



17:45 - 18:05	How I Treat Acute Myeloid Leukemia in Relapse	Stephane de Botton, MD
18:05 - 18:20	HMA-VEN a standard of care for everybody with newly diagnosed Acute Myeloid Leukemia	Courtney Dinardo, MD
18:20 - 18:35	Novel agents in Acute Myeloid Leukemia	Naval Daver, MD
18:35 - 18:45	Q&A	

SESSION 6: LYMPHOMA (II) <i>Moderators: Hassan Ghazal, MD - Adnan Atallah, MD</i>		
18:45 - 19:00	Anchoring the Standard of Care in First-Line Therapy of Diffuse Large B-Cell Lymphoma	Paolo Strati, MD
19:00 - 19:15	Changing Currents in Second Line Therapy of Diffuse Large B-Cell Lymphoma	Gilles Salles, MD
19:15 - 19:30	Management of High-Risk Follicular Lymphoma: Implications for Clinical Practice	Luis Fayad, MD
19:30 - 19:40	Q&A	

Day 2: September 26, 2026



08:30 - 09:00 Registration

SESSION 7: MULTIPLE MYELOMA
Moderators: Khaled Ibrahim, MD - Colette Hanna, MD - Nour Moukalled, MD

09:00 - 09:15	Treatment of High-Risk Multiple Myeloma	Mohamad Mohty, MD
09:15 - 09:30	Treatment of Frail Patients with Multiple Myeloma	Thierry Facon, MD
09:30 - 09:50	Optimizing Bispecific Antibodies and CAR-T for Multiple Myeloma in Clinical Practice	Rachid Baz, MD
09:50 - 10:05	Minimal Residual Disease Negativity the New Endpoint in Multiple Myeloma?	Ahmad Ibrahim, MD

10:05 - 10:15 Q&A

10:15 - 10:45	Symposium : Redefining the future of Multiple Myeloma: Evolving role of Bispecifics <i>Moderator: Jean el Cheikh, MD</i>	Symposium Sponsored by Johnson & Johnson	Ali Bazarbachi, MD
---------------	--	---	--------------------

10:45 - 11:00 Q&A

11:00 - 11:20  **COFFEE BREAK**

Day 2: September 26, 2026



11:20 - 11:50	Symposium : Beyond Efficacy: Optimizing the Safety and Management of Bispecifics in Multiple Myeloma <i>Moderator: Georges Chahine, MD</i>	Symposium Sponsored by Johnson & Johnson	Rachid Baz, MD
11:50 - 12:05	Q&A		
SESSION 8: ACUTE LYMPHOBLASTIC LEUKEMIA <i>Moderators: Jean El Cheikh, MD - Abir Ahmadieh, MD - Tarek Badra, MD - Marcel Massoud, MD</i>			
12:05 - 12:20	How I Treat T-Acute Lymphoblastic Leukemia in 2026		Farhad Ravandi, MD
12:20 - 12:40	Novel Treatments in Newly Diagnosed Acute Lymphoblastic Leukemia		Elias Jabbour, MD
12:40 - 13:00	Treatment of R/R Acute Lymphoblastic Leukemia in 2026		Hagop Kantarjian, MD
13:00 - 13:20	Transplant in Acute Lymphoblastic Leukemia Ph+? Yes (10') / No (10')		Robin Foà, MD vs Elias Jabbour, MD
13:20 - 13:30	Q&A		
13:30 - 14:00	Symposium : ELREXFIO (elranatamab-bcmm): A BCMA-Directed Bispecific Immunotherapy for Adult Patients with Relapsed and Refractory Multiple Myeloma	Symposium Sponsored by Pfizer in partnership with Droguerie Fattal	Ahmad Ibrahim, MD

Day 2: September 26, 2026



SESSION 9: SPECIAL SESSION

Moderator: Elias Jabbour, MD

14:00 - 14:30	Special Lecture: Toward the Cure in all Leukemias	Hagop Kantarjian, MD
14:30 - 14:40	Closing	

PLATINUM

Johnson & Johnson
Innovative Medicine

GOLD



SILVER



SUPPORTERS



SANDOZ



SUPPORTERS



ORGANIZED BY:

INFO MED
Innovating | Executing | Networking
UAE | Lebanon | Kuwait | Iraq